Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft Rejection | 5 | 2025 | 558 | 2.090 |
Why?
|
| Organ Transplantation | 2 | 2025 | 170 | 1.530 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2025 | 1267 | 0.980 |
Why?
|
| Graft Survival | 4 | 2025 | 459 | 0.970 |
Why?
|
| Pancreas Transplantation | 1 | 2024 | 30 | 0.870 |
Why?
|
| Antigens, Surface | 2 | 2014 | 112 | 0.800 |
Why?
|
| Hepatectomy | 1 | 2024 | 125 | 0.790 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 939 | 0.760 |
Why?
|
| Dendritic Cells | 2 | 2014 | 437 | 0.670 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 499 | 0.660 |
Why?
|
| Hypersensitivity | 2 | 2023 | 227 | 0.600 |
Why?
|
| Allergens | 4 | 2025 | 341 | 0.550 |
Why?
|
| Antigens, CD1 | 2 | 2014 | 23 | 0.530 |
Why?
|
| Paramyxoviridae Infections | 2 | 2014 | 49 | 0.520 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 913 | 0.510 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2020 | 134 | 0.510 |
Why?
|
| Glycoproteins | 3 | 2025 | 343 | 0.500 |
Why?
|
| Tissue and Organ Procurement | 4 | 2025 | 254 | 0.460 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 996 | 0.450 |
Why?
|
| Asthma | 3 | 2024 | 914 | 0.430 |
Why?
|
| Postoperative Complications | 4 | 2024 | 3109 | 0.410 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1383 | 0.410 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2014 | 395 | 0.380 |
Why?
|
| Risk Factors | 7 | 2025 | 10953 | 0.380 |
Why?
|
| HIV Infections | 1 | 2024 | 2037 | 0.370 |
Why?
|
| Peanut Hypersensitivity | 2 | 2025 | 88 | 0.360 |
Why?
|
| Cytokines | 3 | 2014 | 1342 | 0.340 |
Why?
|
| Survival Rate | 4 | 2024 | 2127 | 0.330 |
Why?
|
| Lung Transplantation | 6 | 2011 | 354 | 0.320 |
Why?
|
| Epitopes | 2 | 2025 | 321 | 0.320 |
Why?
|
| Time Factors | 6 | 2025 | 6200 | 0.310 |
Why?
|
| Disease Management | 1 | 2014 | 556 | 0.310 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 560 | 0.310 |
Why?
|
| Retrospective Studies | 8 | 2025 | 17550 | 0.290 |
Why?
|
| Risk Assessment | 3 | 2025 | 3679 | 0.290 |
Why?
|
| Adult | 12 | 2025 | 31179 | 0.260 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 5176 | 0.250 |
Why?
|
| Middle Aged | 9 | 2025 | 28438 | 0.250 |
Why?
|
| Young Adult | 6 | 2025 | 10010 | 0.240 |
Why?
|
| Antigens, Plant | 1 | 2025 | 35 | 0.220 |
Why?
|
| Arachis | 2 | 2025 | 76 | 0.220 |
Why?
|
| Prognosis | 2 | 2024 | 4880 | 0.220 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2024 | 7 | 0.220 |
Why?
|
| Vocal Cord Dysfunction | 1 | 2024 | 8 | 0.220 |
Why?
|
| Male | 14 | 2025 | 64488 | 0.210 |
Why?
|
| Humans | 24 | 2025 | 130483 | 0.210 |
Why?
|
| Mouth | 1 | 2024 | 64 | 0.210 |
Why?
|
| Bronchiolitis Obliterans | 5 | 2011 | 41 | 0.210 |
Why?
|
| Thrombomodulin | 2 | 2014 | 18 | 0.210 |
Why?
|
| Female | 14 | 2025 | 70388 | 0.200 |
Why?
|
| HIV | 1 | 2024 | 176 | 0.200 |
Why?
|
| Aged | 6 | 2025 | 20918 | 0.200 |
Why?
|
| Adolescent | 8 | 2025 | 20737 | 0.200 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 54 | 0.180 |
Why?
|
| Fatty Liver | 1 | 2024 | 218 | 0.180 |
Why?
|
| Drug Hypersensitivity | 1 | 2023 | 99 | 0.180 |
Why?
|
| Life Style | 1 | 2024 | 446 | 0.170 |
Why?
|
| Gastroesophageal Reflux | 1 | 2024 | 334 | 0.170 |
Why?
|
| Treatment Outcome | 4 | 2025 | 12843 | 0.160 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2020 | 70 | 0.160 |
Why?
|
| Child | 8 | 2025 | 26101 | 0.150 |
Why?
|
| Microbiota | 1 | 2024 | 435 | 0.150 |
Why?
|
| Ganciclovir | 2 | 2008 | 101 | 0.140 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2017 | 32 | 0.130 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2017 | 126 | 0.130 |
Why?
|
| Vaccines, Synthetic | 1 | 2017 | 319 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 2 | 2008 | 220 | 0.120 |
Why?
|
| Respiratory Tract Infections | 2 | 2009 | 296 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 1076 | 0.110 |
Why?
|
| Macrophages, Alveolar | 1 | 2014 | 51 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2015 | 349 | 0.110 |
Why?
|
| Metapneumovirus | 1 | 2014 | 53 | 0.110 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 47 | 0.100 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2014 | 153 | 0.100 |
Why?
|
| Europe | 1 | 2014 | 365 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2015 | 1227 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2014 | 239 | 0.090 |
Why?
|
| Antiviral Agents | 2 | 2008 | 806 | 0.090 |
Why?
|
| Reoperation | 1 | 2015 | 822 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 1376 | 0.090 |
Why?
|
| Immunoglobulin E | 2 | 2025 | 215 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2014 | 771 | 0.090 |
Why?
|
| Vaccination | 1 | 2017 | 1046 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 1397 | 0.090 |
Why?
|
| Consensus | 1 | 2014 | 529 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2903 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 632 | 0.080 |
Why?
|
| Clarithromycin | 1 | 2011 | 133 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2014 | 381 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 643 | 0.080 |
Why?
|
| Hepatitis B Antibodies | 1 | 2009 | 24 | 0.080 |
Why?
|
| Heart-Lung Transplantation | 1 | 2009 | 16 | 0.080 |
Why?
|
| United States | 2 | 2015 | 11871 | 0.070 |
Why?
|
| Age Factors | 1 | 2015 | 2838 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2025 | 14945 | 0.070 |
Why?
|
| Opportunistic Infections | 1 | 2008 | 72 | 0.070 |
Why?
|
| Lung Diseases, Fungal | 1 | 2008 | 38 | 0.070 |
Why?
|
| Bronchoscopy | 1 | 2008 | 177 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1290 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1930 | 0.060 |
Why?
|
| Lung | 1 | 2014 | 1547 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2009 | 500 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2013 | 2469 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2564 | 0.060 |
Why?
|
| Infant | 2 | 2025 | 13234 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 3039 | 0.060 |
Why?
|
| 2S Albumins, Plant | 1 | 2025 | 6 | 0.060 |
Why?
|
| Industrial Development | 1 | 2024 | 2 | 0.060 |
Why?
|
| Nepal | 1 | 2024 | 25 | 0.050 |
Why?
|
| Agriculture | 1 | 2024 | 30 | 0.050 |
Why?
|
| Skin Tests | 1 | 2025 | 100 | 0.050 |
Why?
|
| Saliva | 1 | 2024 | 125 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 375 | 0.050 |
Why?
|
| Pneumonia | 3 | 2014 | 339 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 29 | 0.050 |
Why?
|
| Penicillins | 1 | 2023 | 152 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2015 | 8518 | 0.050 |
Why?
|
| Bacteria | 1 | 2024 | 518 | 0.040 |
Why?
|
| Omalizumab | 1 | 2020 | 41 | 0.040 |
Why?
|
| Desensitization, Immunologic | 1 | 2021 | 117 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2105 | 0.040 |
Why?
|
| Comorbidity | 1 | 2024 | 1584 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 708 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 2298 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 33862 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 333 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 666 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1226 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 566 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1266 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 982 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2025 | 6450 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 228 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2014 | 173 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 976 | 0.020 |
Why?
|
| Virus Replication | 1 | 2014 | 606 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 5081 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2008 | 22 | 0.020 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2009 | 74 | 0.020 |
Why?
|
| Syndrome | 1 | 2011 | 1160 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 97 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 298 | 0.020 |
Why?
|
| Hepatitis B | 1 | 2009 | 173 | 0.020 |
Why?
|
| Mycoses | 1 | 2009 | 109 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2008 | 330 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 369 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 1491 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2008 | 395 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1610 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 4671 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1395 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3326 | 0.010 |
Why?
|